Receptor-stimulated transamidation induces activation of Rac1 and Cdc42 and the regulation of dendritic spines

Zhen Mi, Tuda Si, Khushboo Kapadia, Qian Li, Nancy A. Muma

Research output: Contribution to journalArticle

Abstract

Regulation of dendritic spines is an important component of synaptic function and plasticity whereas dendritic spine dysregulation is related to several psychiatric and neurological diseases. In the present study, we tested the hypothesis that serotonin (5-HT)2A/2C receptor-induced Rho family transamidation and activation regulates dendritic spine morphology and that activation of multiple types of receptors can induce transglutaminase (TGase)-catalyzed transamidation of small G proteins. We previously reported a novel 5-HT2A receptor downstream effector, TGase-catalyzed serotonylation of the small G protein Rac1 in A1A1v cells, a rat embryonic cortical cell line. We now extend these findings to rat primary cortical cultures which develop dendritic spines; stimulation of 5-HT2A/2C receptors increased transamidation of Rac1 and Cdc42, but not RhoA. Inhibition of TGases significantly decreased transamidation and activation of Rac1 and Cdc42, suggesting that transamidation led to their activation. In primary cortical cultures, stimulation of 5-HT2A/2C receptors by 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) caused a transient dendritic spine enlargement, which was blocked by TGase inhibition. Stimulation of both 5-HT2A and 5-HT2C receptors contributed to DOI-induced Rac1 transamidation in primary cortical cultures as demonstrated by selective antagonists. Furthermore, stimulation of muscarinic acetylcholine receptors and NMDA receptors also increased TGase-catalyzed Rac1 activation in SH-SY5Y cells and N2a cells, respectively. Receptor-stimulated TGase-catalyzed transamidation of Rac1 occurs at Q61, a site previously reported to be important in the inactivation of Rac1. These studies demonstrate that TGase-catalyzed transamidation and activation of small G proteins results from stimulation of multiple types of receptors and this novel signaling pathway can regulate dendritic spine morphology and plasticity.

Original languageEnglish (US)
Pages (from-to)93-105
Number of pages13
JournalNeuropharmacology
Volume117
DOIs
StatePublished - May 1 2017

Fingerprint

Dendritic Spines
Transglutaminases
Receptor, Serotonin, 5-HT2A
Monomeric GTP-Binding Proteins
Receptor, Serotonin, 5-HT2C
Neuronal Plasticity
Muscarinic Receptors
N-Methyl-D-Aspartate Receptors
Psychiatry
Serotonin
Cell Line

Keywords

  • Muscarinic receptors
  • NMDA receptors
  • Serotonin 2A/2C receptors
  • Serotonylation
  • Transglutaminase

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Receptor-stimulated transamidation induces activation of Rac1 and Cdc42 and the regulation of dendritic spines. / Mi, Zhen; Si, Tuda; Kapadia, Khushboo; Li, Qian; Muma, Nancy A.

In: Neuropharmacology, Vol. 117, 01.05.2017, p. 93-105.

Research output: Contribution to journalArticle

Mi, Zhen ; Si, Tuda ; Kapadia, Khushboo ; Li, Qian ; Muma, Nancy A. / Receptor-stimulated transamidation induces activation of Rac1 and Cdc42 and the regulation of dendritic spines. In: Neuropharmacology. 2017 ; Vol. 117. pp. 93-105.
@article{eb18fe96aed848b5a13a51a3a7c784c1,
title = "Receptor-stimulated transamidation induces activation of Rac1 and Cdc42 and the regulation of dendritic spines",
abstract = "Regulation of dendritic spines is an important component of synaptic function and plasticity whereas dendritic spine dysregulation is related to several psychiatric and neurological diseases. In the present study, we tested the hypothesis that serotonin (5-HT)2A/2C receptor-induced Rho family transamidation and activation regulates dendritic spine morphology and that activation of multiple types of receptors can induce transglutaminase (TGase)-catalyzed transamidation of small G proteins. We previously reported a novel 5-HT2A receptor downstream effector, TGase-catalyzed serotonylation of the small G protein Rac1 in A1A1v cells, a rat embryonic cortical cell line. We now extend these findings to rat primary cortical cultures which develop dendritic spines; stimulation of 5-HT2A/2C receptors increased transamidation of Rac1 and Cdc42, but not RhoA. Inhibition of TGases significantly decreased transamidation and activation of Rac1 and Cdc42, suggesting that transamidation led to their activation. In primary cortical cultures, stimulation of 5-HT2A/2C receptors by 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) caused a transient dendritic spine enlargement, which was blocked by TGase inhibition. Stimulation of both 5-HT2A and 5-HT2C receptors contributed to DOI-induced Rac1 transamidation in primary cortical cultures as demonstrated by selective antagonists. Furthermore, stimulation of muscarinic acetylcholine receptors and NMDA receptors also increased TGase-catalyzed Rac1 activation in SH-SY5Y cells and N2a cells, respectively. Receptor-stimulated TGase-catalyzed transamidation of Rac1 occurs at Q61, a site previously reported to be important in the inactivation of Rac1. These studies demonstrate that TGase-catalyzed transamidation and activation of small G proteins results from stimulation of multiple types of receptors and this novel signaling pathway can regulate dendritic spine morphology and plasticity.",
keywords = "Muscarinic receptors, NMDA receptors, Serotonin 2A/2C receptors, Serotonylation, Transglutaminase",
author = "Zhen Mi and Tuda Si and Khushboo Kapadia and Qian Li and Muma, {Nancy A.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.neuropharm.2017.01.034",
language = "English (US)",
volume = "117",
pages = "93--105",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Receptor-stimulated transamidation induces activation of Rac1 and Cdc42 and the regulation of dendritic spines

AU - Mi, Zhen

AU - Si, Tuda

AU - Kapadia, Khushboo

AU - Li, Qian

AU - Muma, Nancy A.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Regulation of dendritic spines is an important component of synaptic function and plasticity whereas dendritic spine dysregulation is related to several psychiatric and neurological diseases. In the present study, we tested the hypothesis that serotonin (5-HT)2A/2C receptor-induced Rho family transamidation and activation regulates dendritic spine morphology and that activation of multiple types of receptors can induce transglutaminase (TGase)-catalyzed transamidation of small G proteins. We previously reported a novel 5-HT2A receptor downstream effector, TGase-catalyzed serotonylation of the small G protein Rac1 in A1A1v cells, a rat embryonic cortical cell line. We now extend these findings to rat primary cortical cultures which develop dendritic spines; stimulation of 5-HT2A/2C receptors increased transamidation of Rac1 and Cdc42, but not RhoA. Inhibition of TGases significantly decreased transamidation and activation of Rac1 and Cdc42, suggesting that transamidation led to their activation. In primary cortical cultures, stimulation of 5-HT2A/2C receptors by 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) caused a transient dendritic spine enlargement, which was blocked by TGase inhibition. Stimulation of both 5-HT2A and 5-HT2C receptors contributed to DOI-induced Rac1 transamidation in primary cortical cultures as demonstrated by selective antagonists. Furthermore, stimulation of muscarinic acetylcholine receptors and NMDA receptors also increased TGase-catalyzed Rac1 activation in SH-SY5Y cells and N2a cells, respectively. Receptor-stimulated TGase-catalyzed transamidation of Rac1 occurs at Q61, a site previously reported to be important in the inactivation of Rac1. These studies demonstrate that TGase-catalyzed transamidation and activation of small G proteins results from stimulation of multiple types of receptors and this novel signaling pathway can regulate dendritic spine morphology and plasticity.

AB - Regulation of dendritic spines is an important component of synaptic function and plasticity whereas dendritic spine dysregulation is related to several psychiatric and neurological diseases. In the present study, we tested the hypothesis that serotonin (5-HT)2A/2C receptor-induced Rho family transamidation and activation regulates dendritic spine morphology and that activation of multiple types of receptors can induce transglutaminase (TGase)-catalyzed transamidation of small G proteins. We previously reported a novel 5-HT2A receptor downstream effector, TGase-catalyzed serotonylation of the small G protein Rac1 in A1A1v cells, a rat embryonic cortical cell line. We now extend these findings to rat primary cortical cultures which develop dendritic spines; stimulation of 5-HT2A/2C receptors increased transamidation of Rac1 and Cdc42, but not RhoA. Inhibition of TGases significantly decreased transamidation and activation of Rac1 and Cdc42, suggesting that transamidation led to their activation. In primary cortical cultures, stimulation of 5-HT2A/2C receptors by 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) caused a transient dendritic spine enlargement, which was blocked by TGase inhibition. Stimulation of both 5-HT2A and 5-HT2C receptors contributed to DOI-induced Rac1 transamidation in primary cortical cultures as demonstrated by selective antagonists. Furthermore, stimulation of muscarinic acetylcholine receptors and NMDA receptors also increased TGase-catalyzed Rac1 activation in SH-SY5Y cells and N2a cells, respectively. Receptor-stimulated TGase-catalyzed transamidation of Rac1 occurs at Q61, a site previously reported to be important in the inactivation of Rac1. These studies demonstrate that TGase-catalyzed transamidation and activation of small G proteins results from stimulation of multiple types of receptors and this novel signaling pathway can regulate dendritic spine morphology and plasticity.

KW - Muscarinic receptors

KW - NMDA receptors

KW - Serotonin 2A/2C receptors

KW - Serotonylation

KW - Transglutaminase

UR - http://www.scopus.com/inward/record.url?scp=85012248689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012248689&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2017.01.034

DO - 10.1016/j.neuropharm.2017.01.034

M3 - Article

C2 - 28161375

AN - SCOPUS:85012248689

VL - 117

SP - 93

EP - 105

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -